Mandate

Vinge advises HH Ferries

September 21, 2018 EU, Competition and Regulatory

Vinge has advised HH Ferries in an action before the EU General Court in Luxembourg in state aid proceedings which primarily relate to state guarantees.

The General Court approved HH Ferries’ action due to, among other things, the European Commission’s deficient review of the amount and time limits as well as the support measures’ proportionality and necessity and thus set aside the European Commission’s decision. 

Vinge’s team primarily consisted of Martin Johansson at the Brussels office as well as Rikard Azelius and Pär Remnelid at the Skåne office.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026